menu
    • menu
    [{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ University of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ University of Alabama"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Hospital Southampton","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ University Hospital Southampton","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ University Hospital Southampton"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BerGenBio ASA \/ BerGenBio","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ BerGenBio"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Meteva AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Bemcentinib","moa":"AXL kinase","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Meteva AS","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Meteva AS"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Tempus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Tempus","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Tempus"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BerGenBio ASA

    Menu

    BerGenBio ASA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

                            Details : BGB 324 (bemcentinib) is an AXL inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of STK11 mutated NSCLC.

                            Brand Name : BGB 324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2024

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Tempus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BerGenBio Collaborates with Tempus to Accelerate STK11m NSCLC Development

                            Details : Through the collaboration, BerGenBio will advance the selective AXL inhibitor, BGB 324 (bemcentinib) for the treatment of non-small cell lung cancer patients with stk11 mutations.

                            Brand Name : BGB 324

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 20, 2024

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Tempus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Selects 2nd Dose in Phase 2a STK11m Non-Small Lung Cancer Trial

                            Details : BGB 324 (bemcentinib) is an AXL inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of STK11 mutated NSCLC.

                            Brand Name : BGB 324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Initiates Phase 2a In First Line NSCLC Patients With STK11 Mutation

                            Details : BGB 324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL). It is being evaluated for the treatment of STK11 mutated Non-Small Lung Cancer.

                            Brand Name : BGB 324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2024

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Presents New Preclinical Data for Bemcentinib in Severe Respiratory Infections

                            Details : BGB324 (bemcentinib) is a first-in-class oral AXL inhibitor, currently evaluated in preclinical studies for treating Respiratory Syncytial Virus infections.

                            Brand Name : BGB324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : Bemcentinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell...

                            Details : BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being developed for the treament of NSCLC.

                            Brand Name : BGB324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2023

                            Lead Product(s) : Bemcentinib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ N...

                            Details : BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being investigated for non-small cell lung cancer (NSCLC).

                            Brand Name : BGB324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 15, 2023

                            Lead Product(s) : Bemcentinib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meteva AS

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BerGenBio ASA Secures NOK 100 Million Shareholder Loan Facility from Meteva AS

                            Details : The facility will enable BerGenBio to continue its previously announced focused strategy of advancing its lead compound bemcentinib (BGB324) in 1st line Non-Small Cell Lung Cancer (NSCLC) and hospitalized COVID-19 patients.

                            Brand Name : BGB324

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Bemcentinib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meteva AS

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mipasetamab Uzoptirine,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : ADC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent an...

                            Details : ADCT-601 (mipasetamab uzoptirine) is composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using GlycoConnect™ technology (licensed from Synaffix BV) to a linker with a pyrrolobenzodiazepine (PBD)-dim...

                            Brand Name : ADCT-601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 27, 2022

                            Lead Product(s) : Mipasetamab Uzoptirine,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : ADC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bergenbio Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Pati...

                            Details : Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy.

                            Brand Name : BGB324

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2022

                            Lead Product(s) : Bemcentinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth